1. Home
  2. ADAG vs BUUU Comparison

ADAG vs BUUU Comparison

Compare ADAG & BUUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$4.47

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

BUUU

BUUU Group Limited Class A Ordinary Share

HOLD

Current Price

$24.01

Market Cap

299.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
BUUU
Founded
2011
2017
Country
China
Hong Kong
Employees
N/A
16
Industry
Biotechnology: Pharmaceutical Preparations
Services-Misc. Amusement & Recreation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
260.3M
299.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ADAG
BUUU
Price
$4.47
$24.01
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.25
N/A
AVG Volume (30 Days)
270.7K
24.4K
Earning Date
04-01-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$347.19
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$3.97
52 Week High
$4.85
$27.45

Technical Indicators

Market Signals
Indicator
ADAG
BUUU
Relative Strength Index (RSI) 62.38 58.70
Support Level $3.21 $13.78
Resistance Level $4.66 $25.99
Average True Range (ATR) 0.45 2.58
MACD 0.09 0.27
Stochastic Oscillator 75.46 44.88

Price Performance

Historical Comparison
ADAG
BUUU

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About BUUU BUUU Group Limited Class A Ordinary Share

BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.

Share on Social Networks: